All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
About the MDS Hub
The MDS Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in myelodysplastic syndromes (MDS). Our aim is to enhance knowledge in MDS through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
The MDS Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
Vision
For every treatment team and researcher to have instant access to expert opinions and the latest evidence-based information in MDS, to aid in treatment decisions and improve the lives of patients with MDS globally.
Mission
The MDS Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders and endorsed by expert societies the MDS Hub supports HCPs worldwide.
Partnerships
The MDS Hub was founded in partnership with the European LeukemiaNet (ELN). The ELN is a publicly-funded network of excellence, where clinicians and scientists improve therapy options for patients with leukemia worldwide. Together, they look to define strategies to improve leukemia characterization, its common diagnostic procedures and therapeutic standards, as well as to facilitate clinical and fundamental research. This approach results in the advancement of leukemia research and it supports equal access for all patients to the best possible care.